A novel in vitro model system for studying the action of ara-C

被引:12
|
作者
Hickey, R
Ross, D
Ross, D
Cuddy, D
Malkas, L
机构
[1] UNIV MARYLAND,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BALTIMORE,MD 21201
[2] UNIV MARYLAND,SCH PHARM,DEPT PHARMACEUT SCI,BALTIMORE,MD 21201
[3] UNIV MARYLAND,SCH MED,DEPT MED,BALTIMORE,MD 21201
[4] BALTIMORE VET MED CTR,BALTIMORE,MD
[5] UNIV MARYLAND,CTR CANC,DIV DEV THERAPEUT,BALTIMORE,MD 21201
[6] UNIV BALTIMORE,MOLEC & CELLULAR BIOL PROGRAM,BALTIMORE,MD 21201
关键词
cytosine arabinoside; anticancer drugs; mammalian cells; multiprotein DNA replication complex; in vitro model system;
D O I
10.1007/s002800050496
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C) has proven to be one of the most effective agents available for the treatment of acute leukemia. While ara-C has been implicated as a potent inhibitor of mammalian cell DNA replication, the specific mechanism by which ara-C kills cells is not known. In this report we describe the development of an in vitro model system to study the molecular mechanism of ara-CMP incorporation into DNA. This model system makes use of a recently described human cell multiprotein DNA replication complex (MRC) that is competent to replicate DNA in vitro. The MRC can successfully incorporate ara-CMP into replicating DNA at internucleotide positions. These results are similar to those described for studies using intact cells. This MRC-driven in vitro replication system may therefore serve as a powerful model for the study of anticancer agents that directly affect human cell DNA synthesis.
引用
收藏
页码:366 / 372
页数:7
相关论文
共 50 条
  • [31] POTENTIATION OF THE CLASTOGENIC ACTION OF ELLIPTICINE BY THE DNA-REPAIR INHIBITORS CAFFEINE AND ARA-C
    SAKAMOTOHOJO, ET
    TAKAHASHI, CS
    MUTATION RESEARCH, 1990, 234 (06): : 402 - 403
  • [32] MICROFLUORIMETRIC EVALUATION OF CELL KILL KINETICS WITH ARA-C IN-VITRO AND IN-VIVO
    YATAGANAS, X
    CLARKSON, BD
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1974, 15 (MAR): : 133 - 133
  • [33] THE CYTOSINE-ARABINOSIDE (ARA-C) SYNDROME
    CASTLEBERRY, RP
    CRIST, WM
    HOLBROOK, T
    MALLUH, A
    GADDY, D
    MEDICAL AND PEDIATRIC ONCOLOGY, 1981, 9 (03): : 257 - 264
  • [34] Too much ara-C? Not enough daunorubicin?
    Feldman, Eric J.
    BLOOD, 2011, 117 (08) : 2299 - 2300
  • [35] Ara-C reversibly inhibits cell proliferation in hamster tooth germs in vitro.
    Lyaruu, DM
    vanDuin, MA
    Bervoets, TJM
    Woltgens, JHM
    Bronckers, ALJJ
    JOURNAL OF DENTAL RESEARCH, 1997, 76 : 119 - 119
  • [36] SATURATION OF ARA-CTP ACCUMULATION DURING HIGH-DOSE ARA-C THERAPY - PHARMACOLOGICAL RATIONALE FOR INTERMEDIATE-DOSE ARA-C
    PLUNKETT, W
    LILIEMARK, JO
    ESTEY, E
    KEATING, MJ
    SEMINARS IN ONCOLOGY, 1987, 14 (02) : 159 - 166
  • [37] Personalization of Induction Therapy for Pediatric AML to Ara-C plus Dauno plus Etoposide (ADE) or Clofarabine plus Ara-C According to a Polygenic Ara-C SNP Score-ACS10
    Lamba, Jatinder K.
    Marrero, Richard J.
    Elsayed, Abdelrahman H.
    Cao, Xueyuan
    Wu, Huiyun
    Inaba, Hiroto
    Raimondi, Susana C.
    Pui, Ching-Hon
    Ribeiro, Raul C.
    Rubnitz, Jeffrey E.
    Pounds, Stanley B.
    BLOOD, 2022, 140 : 1039 - 1040
  • [38] SYNERGISTIC IMMUNOSUPPRESSION WITH ASPARAGINASE (A'ASE) AND ARA-C
    CAPIZZI, RL
    GOLDEN, R
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 160 - 160
  • [39] IMMUNOSUPPRESSIVE ACTIVITY OF ARA-C (CYTARABINE) AND DERIVATIVES
    GRAY, GD
    TRANSPLANTATION PROCEEDINGS, 1973, 5 (03) : 1203 - 1209
  • [40] ARA-C RELATED RED EAR SYNDROME
    Sahu, Kamal Kant
    Yanamandra, Uday
    Malhotra, Pankaj
    ENT-EAR NOSE & THROAT JOURNAL, 2019, 98 (03) : 169 - 170